This study is part of the Health Canada approval requirement for JINARC™ (tolvaptan) and is an observational, non-interventional study (NIS) describing the impact of tolvaptan on ADPKD-related burden of illness as measured with a set of Patient Reported Outcome (PRO) Questionnaires. The study is also describing the time to renal replacement therapy (RRT), such as dialysis and transplantation, and the long-term mortality rate and causes (i.e. renal and hepatic), in ADPKD patients treated with JINARC™ (tolvaptan)

Inclusion Criteria:

• ADPKD patients ≥18 years old at the time of tolvaptan initiation
• The treating physician must have reached the decision to treat the patient with JINARC™ (tolvaptan) as per the Canadian Product Monograph prior to and independently of soliciting the patient to participate in the study
• The patient or legal guardian must have signed an informed consent indicating the understanding of the study and allowing the use of their anonymous data for the purposes of the study

Exclusion Criteria:

• The patient does not comprehend or refuses to sign the informed consent
• The patient has any contraindications to the use of JINARC™ (tolvaptan) as specified in the Canadian Product Monograph
• The patient has any condition which, as per the judgment of the treating physician, prohibits them from participating in the study

The study population will be adult patients newly prescribed with JINARC™ (tolvaptan) for the treatment of ADPKD, or patients who are on-treatment with JINARC™ (tolvaptan) at the time of enrolment. Investigator must be ADPKD experts qualified by experience and ability to perform the study.

Participants consenting to share their data are consented and identified as such in the clinical database.

During the course of 2024, a CSR covering the study period from 2016 to the end of 2023 will be produced. Another CSR will be produced in 2026, after the conclusion of the 120-month study period.